Trial Profile
A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML In First Complete Remission
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Ponatinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Acronyms PONATINIB-AML
- 06 Aug 2020 Planned End Date changed from 1 Sep 2020 to 1 Nov 2023.
- 06 Aug 2020 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2020.
- 06 Aug 2020 Status changed from recruiting to active, no longer recruiting.